When to induce labour to limit risk in pregnancy hypertension

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
01/11/2018		[X] Protocol		
Registration date 05/12/2018	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
25/06/2025	Pregnancy and Childbirth			

Plain English summary of protocol

Background and study aims

This study is looking to enrol pregnant women who have high blood pressure (hypertension) during their pregnancy. High blood pressure increases the risk of harm to the mother and to her baby, and the study is being conducted to see when it is best to deliver the baby in order to minimise this risk as much as possible. In the UK, up to 55,000 pregnant women each year have high blood pressure during their pregnancies. It is not known whether delivery should be started before the onset of spontaneous labour that usually occurs at term, defined as 37-42 weeks (within which is the 'due date' of 40 weeks of pregnancy). Early planned delivery at term (at 37-38 weeks) may reduce stillbirth and complications for the mother, such as separation of the placenta from the wall of the womb, or development of pre-eclampsia, a more concerning form of high blood pressure that is associated with protein in the urine or other problems for mothers and babies and possibly Caesarean delivery. However, early planned delivery at term may also cause harm, including newborn health problems such as breathing or other difficulties that may require the baby to need care in a newborn unit. This study is looking at the experiences of 1,080 pregnant women with hypertension who have been pregnant for at least 36 to 37 weeks to see if delivering their baby between 38 weeks plus zero days to 38 weeks plus 3 days gives a better outcome for the mother and her baby than does waiting for at least 40 weeks for the women to deliver. At the moment there is no conclusive evidence to say which delivery time is best. Different doctors do different things and this is why this study is needed.

Who can participate?

Women aged 16 years and over who are 36 to 37 weeks pregnant and have hypertension

What does the study involve?

Participants are randomly allocated to planned birth at 38 weeks, or planned observation of pregnancy until at least 40 weeks (unless an indication for birth develops). The research midwife contacts participants weekly until the birth. Before leaving hospital after birth, participants are asked to complete a two-page questionnaire about their experience of childbirth. At 6 weeks after birth, they are sent a very brief online questionnaire via a text message, to find out about any serious problems that the mothers or babies may have experienced since leaving hospital after birth. There is support throughout from dedicated research midwives.

What are the possible benefits and risks of participating?

Mothers and babies are closely monitored. The knowledge gained from this research might in the future benefit many, many women with high blood pressure in pregnancy. The study involves no new interventions and has no added risks to the mother or baby; instead, the study measures risk.

Where is the study run from?

- 1. Guy's and St Thomas' NHS Foundation Trust (UK)
- 2. Leeds Teaching Hospitals NHS Trust (UK)
- 3. Liverpool Women's Hospital (UK)
- 4. Birmingham Women's Hospital (UK)
- 5. West Middlesex Hospital (UK)
- 6. Croydon University Hospital (UK)
- 7. Leicester Royal Infirmary (UK)
- 8. Nottingham City Hospital (UK)
- 9. Queen's Medical Centre (UK)
- 10. Princess Anne Hospital (UK)
- 11. St Mary's Hospital (UK)
- 12. Poole Hospital (UK)
- 13. Norfolk & Norwich University Hospital NHS Foundation Trust (UK)
- 14. York Hospital (UK)
- 15. Singleton Hospital (UK)
- 16. North West Anglia NHS Foundation Trust (UK)
- 17. Royal United Hospital, Bath (UK)
- 18. South Tees Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for? June 2018 to January 2024

Who is funding the study?
NIHR Health Technology Assessment Programme (UK)

Who is the main contact? Katie Kirkham will@trials.bham.ac.uk

Contact information

Type(s)

Scientific

Contact name

Ms Katie Kirkham

Contact details

Birmingham Clinical Trials Unit (BCTU) Institute of Applied Health Research Public Health Building University of Birmingham Edgbaston Birmingham United Kingdom B15 2TT +44 (0)1214159109 will@trials.bham.ac.uk

Additional identifiers

Protocol serial number

252294; HTA 16/167/123

Study information

Scientific Title

When to Induce Labour to Limit risk in pregnancy hypertension - a multi-centre, randomised controlled trial in women with chronic or gestational hypertension

Acronym

WILL

Study objectives

Earlier delivery at term may be beneficial to women with chronic or gestational hypertension, without increasing risk to babies or caesarean delivery.

The trial will investigate the clinical effectiveness and cost-consequences of planned early term delivery at 38+0 to 38+3 weeks gestation, compared with expectant care at term until at least 40+0 weeks gestation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 10/01/2019, London - Fulham Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, Tel: +44 (0)207 104 8021; Email: nrescommittee.londonfulham@nhs.net), REC ref: 18/LO/2033, Protocol number: 252294, IRAS project ID: 252294

Study design

Open-label interventional multicentre non-blinded study

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Chronic or gestational hypertension that develops by 37+6 weeks gestation

Interventions

Current interventions as of 07/07/2023:

Randomisation will be provided through a bespoke database provided by BCTU.

- 1. Planned early-term delivery at 38+0 to 38+3 weeks by labour induction (local protocol) or elective Caesarean (if previously indicated)
- 2. Usual care at term until, with maternal and fetal monitoring (local protocol), awaiting spontaneous labour or delivery indicated by clinical need (e.g., refractory severe hypertension or pre-eclampsia)

Follow-up: 31/11/2018 to 31/01/2023.

Previous interventions:

Randomisation will be provided through a bespoke database provided by BCTU.

- 1. Planned early-term delivery at 38+0 to 38+3 weeks by labour induction (local protocol) or elective Caesarean (if previously indicated)
- 2. Expectant care at term until at least 40+0 weeks, with maternal and fetal monitoring (local protocol), awaiting spontaneous labour or delivery indicated by clinical need (e.g., refractory severe hypertension or pre-eclampsia)

Follow-up: 31/11/2018 to 20/04/2022.

Intervention Type

Procedure/Surgery

Primary outcome(s)

- 1. Maternal co-primary outcome: Composite of poor maternal outcome until primary hospital discharge home or 28 days after delivery birth (whichever is earlier), defined as:
- 1.1. Severe hypertension (i.e., systolic BP (sBP) ≥160 or diastolic BP ≥110mmHg); or
- 1.2. Maternal death: or
- 1.3. Maternal morbidity defined as any of the following: GCS<13; stroke; TIA; eclampsia; blindness; uncontrolled hypertension; inotropic support; pulmonary oedema; respiratory failure; SpO2 <90%; myocardial ischaemia or infarction; hepatic dysfunction, hepatic haematoma or rupture; acute kidney injury or dialysis; platelet count <50x109/L; transfusion; or placental abruption. These were adapted from a Delphi consensus in hypertensive pregnancy. Measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 2. Neonatal co-primary outcome: Neonatal care unit admission for ≥ 4 hours, measured by review of maternity or neonatal notes/electronic records until primary hospital discharge home or 28 days after delivery birth (whichever is earlier)

Key secondary outcome(s))

Maternal:

- 1. Caesarean delivery, measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 2. Instrumental vaginal delivery or Caesarean delivery (vs. spontaneous vaginal delivery), measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 3. Individual components of maternal co-primary outcome, measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 4. Elevated liver enzymes, measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 5. Platelet count <100x109/L, measured by review of maternity notes/electronic records until

primary hospital discharge home or 28 days after birth (whichever is earlier)

- 6. Pre-eclampsia, measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 7. Sepsis, measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 8. Postpartum haemorrhage (PPH), measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 9. Intensive care unit (ITU) admission, measured by review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)

Potential co-interventions (only among women randomised):

- 1. Antihypertensive therapy taken, measured using review of maternity notes/electronic records ntil uprimary hospital discharge home or 28 days after birth (whichever is earlier)
- 2. Magnesium sulphate, measured using review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 3. Bedrest at home, measured using review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 4. Use of home BP monitoring, measured using review of maternity notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 5. Maternal blood/urine testing at lab before delivery admission, measured using review of maternity notes/electronic records after randomisation before birth
- 6. Office/clinic visits, measured using review of maternity notes/electronic records after randomisation before birth
- 7. Obstetrical day unit visits, measured using review of maternity notes/electronic records after randomisation before birth
- 8. Acute care visits, measured using review of maternity notes/electronic records after randomisation before birth
- 9. Antenatal admissions, measured using review of maternity notes/electronic records after randomisation before birth
- 10. Fetal cardiotocography, measured using review of maternity notes/electronic records after randomisation before birth
- 11. Fetal ultrasound, measured using review of maternity notes/electronic records after randomisation before birth
- 1. Clinical indications for delivery in the expectant care arm, measured using review of maternity notes/electronic records after randomisation before birth
- 2. Maternal satisfaction, measured using Childbirth Experience Questionnaire 2.0 until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 3. 'Poor maternal outcome'‡, measured using review of maternity notes/electronic records and postpartum questionnaire at 6 weeks after birth
- 4. Infection of the Caesarean wound, episiotomy or vaginal tear, as applicable‡, measured using postpartum questionnaire at 6 weeks after birth

Neonatal:

- 1. Neonatal care unit admission, measured using review of maternity or neonatal notes /electronic records and 6 week postpartum questionnaire until 28 days after birth
- 2. Indication for neonatal care unit admission ≥ 4 hours, measured using review of neonatal notes /electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 3. Respiratory morbidity, measured using review of neonatal notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 4. Hypoxic-ischaemic encephalopathy (HIE), measured using review of neonatal notes/electronic

records until primary hospital discharge home or 28 days after birth (whichever is earlier)

- 5. Sepsis, measured using review of neonatal notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 6. Major operation, measured using review of neonatal notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 7. Intra-uterine fetal death, assessed by ultrasound doppler antepartum and lack of vital signs at birth
- 8. Neonatal death, measured using review of neonatal notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 9. Breastfeeding established, measured using review of neonatal notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)
- 10. Exclusive breastfeeding, measured using review of neonatal notes/electronic records until primary hospital discharge home or 28 days after birth (whichever is earlier)

Health Economics

Cost-consequence analysis from NHS perspective, measured using review of neonatal notes /electronic records for individual-level data until primary hospital discharge home or 28 days after birth (whichever is earlier)

‡ Only among women randomised

Completion date

31/01/2024

Eligibility

Key inclusion criteria

- 1. Maternal age ≥16 years
- 2. Diagnosis of chronic or gestational hypertension
- 3. Singleton pregnancy
- 4. Live fetus
- 5. Gestational age of 36+0 to 37+6 weeks
- 6. Able to give written informed consent to participate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Total final enrolment

Key exclusion criteria

- 1. Contraindication to either one of the trial arms (e.g., evidence of pre-eclampsia)
- 2. Severe hypertension [i.e., blood pressure (BP) \geq 160mmHg systolic or \geq 110mmHg diastolic] until BP falls below this level (i.e. it is 'controlled')
- 3. Major fetal anomaly anticipated to require neonatal unit admission
- 4. Participation in another timing of delivery trial

NOTE: Women with co-morbidities (e.g., diabetes) and fetal size will not be exclusion criteria

Date of first enrolment

03/06/2019

Date of final enrolment

30/04/2022

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre

Guy's and St Thomas' NHS Foundation Trust

R&D Department 16th Floor, Tower Wing Great Maze Pond London United Kingdom SE1 9RT

Study participating centre Leeds Teaching Hospitals NHS Trust

Leeds United Kingdom LS9 7TF

Study participating centre Liverpool Women's Hospital

Crown St Liverpool United Kingdom L8 7SS

Study participating centre Birmingham Women's Hospital

Mindlesohn Way Birmingham United Kingdom B15 2TG

Study participating centre West Middlesex Hospital

Twickenham Rd Isleworth United Kingdom TW7 6AF

Study participating centre Croydon University Hospital

530 London Road Croydon United Kingdom CR7 7YE

Study participating centre Leicester Royal Infirmary

Infirmary Square Leicester United Kingdom LE1 5WW

Study participating centre Nottingham City Hospital

Hucknall Rd Nottingham United Kingdom NG5 1PB

Study participating centre

Queen's Medical Centre

Derby Road Nottingham United Kingdom NG7 2UH

Study participating centre Princess Anne Hospital

Coxford Rd Southampton United Kingdom SO16 5YA

Study participating centre St Mary's Hospital

Oxford Road Manchester United Kingdom M13 9WL

Study participating centre

Poole Hospital

St Mary's Rd Poole United Kingdom BH15 2BH

Study participating centre

Norfolk & Norwich University Hospital NHS Foundation Trust

Colney Ln Norwich United Kingdom NR4 7UY

Study participating centre

York Hospital

Wigginton Rd York United Kingdom YO31 8HE

Study participating centre Singleton Hospital

Sketty Ln Sketty Swansea United Kingdom SA2 8QA

Study participating centre North West Anglia NHS Foundation Trust

Parkway Hinchingbrooke Huntingdon United Kingdom PE29 6NT

Study participating centre North West Anglia NHS Foundation Trust

Edith Cavell Campus Bretton Gate Peterborough United Kingdom PE3 9GZ

Study participating centre Royal United Hospital

Combe Park Bath United Kingdom BA1 3NG

Study participating centre South Tees Hospitals NHS Foundation Trust

James Cook Hospital Marton Rd Middlesbrough United Kingdom TS4 3BW

Sponsor information

Organisation

King's College London

ROR

https://ror.org/0220mzb33

Organisation

Guy's and St Thomas' NHS Foundation Trust

ROR

https://ror.org/00j161312

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Laura Magee (laura.a.magee@kcl.ac.uk), anonymised data will be shared at the end of the trial.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article		26/11/2024	28/11 /2024	Yes	No
Results article	Mixed Methods Analysis	24/06/2025	25/06 /2025	Yes	No
Protocol article		03/04/2023	30/05 /2024	Yes	No
HRA research summary			28/06 /2023	No	No
Other publications	Adaptations to trial during COVID pandemic	21/10/2022	24/10 /2022	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11 /2025	No	Yes
Study website	Study website	11/11/2025	11/11 /2025	No	Yes